March 2, 2012
-- Biomiga Diagnostics, a molecular diagnostics company, today announced the development of lateral flow point-of-care Therapeutic Drug Monitoring (TDM) assays for Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH). Hormone manipulation therapies, such as long-acting gonadotropin-
releasing hormone (GnRH) agonists, are used in the treatment of estrogen-dependent forms of breast cancer, as well as prostate cancer, because down-regulation of LH) and FSH leads to a decline in hormonal support to the ovary and testis. Effectiveness of hormone manipulation therapies can be monitored by quantitation of LH and/or FSH. Traditionally, these hormones are measured by ELISA assays that require blood to be drawn at either a doctor’s office or a diagnostic laboratory. Here, Dr. Larn Hwang and colleagues describe the development of rapid point-of-care tests for detection of these hormones that are quantitative and applicable to plasma, serum, as well as urine. As TDM, these tests should allow for more effective dosing of the patients and thereby improving effectiveness of hormone manipulation therapy. The tests are also patient-centric, inviting better compliance and patient participation in personalizing his/her treatment. The simplicity of the assays would allow for field deployment during clinical development for population pharmacokinetics as well as deployment in underdeveloped regions lacking access to central laboratories. These findings will be presented at the 2012 American Association for Cancer Research Annual Meeting in Chicago, Illinois.
Abstract #3618. Rapid and quantitative lateral flow point-of-care Therapeutic Drug Monitoring (TDM) assays for LH and FSH. Larn Hwang, Chao Hsiao, Kouros Motamed, Vuong Trieu. BIOMIGA DIAGNOSTICS, Fountain Valley, CA. Presentation Time: Tuesday, Apr 03, 2012, 8:00 AM -12:00 PM. Location: McCormick Place West (Hall F), Poster Section 23.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 laboratory, translational and clinical researchers;
health care professionals;
and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs.
About Biomiga Diagnostics
mission is to transform healthcare by point-of-care tests for Therapeutic Drug Monitoring. These tests are simple to use and require no specialized equipment or trained personnel. They are rapid with results within 20 minutes of blood collection. They are convenient and can be deployed at home, in doctor’s office, in emergency rooms, or in centralized laboratories. Moreover, they are quantitative with linear response range similar to tests performed at centralized laboratories. These proprietary diagnostic devices deployed at point-of-care are the solution to personalized healthcare, allowing the dosing of the right patient with the right drug at the right dose.
The executives of Biomiga Diagnostics are a group of pharmaceutical veterans who believe that the next revolution in medicine is in point-of-care tests for optimal drug dosing. With more than a decade of drug development experience each, the leadership team has expertise ranging from basic/applied research, preclinical/
clinical development, pharmacokinetics/
pharmacodynamics biomarker development, mobile technology, regulatory, legal, marketing and business development.http://www.biomigadiagnostics.com
Larn Hwang PhD
Chief Operating Officer
Kouros Motamed PhD
Chief Technology Officer
# # #
Biomiga Diagnostics, maker of quantitative point-of-care tests for Therapeutic Drug Monitoring to drive personalized medicine,